Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
4.040
-0.010 (-0.25%)
Oct 23, 2026, 4:00 PM EDT - Market closed
Atea Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
324.03M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 351.37M | 302.73M | 622.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Enanta Pharmaceuticals | 65.26M |
| vTv Therapeutics | 36.84M |
| Scribe Therapeutics | 33.30M |
| Orchestra BioMed Holdings | 31.98M |
| Arcturus Therapeutics Holdings | 29.37M |
| Capricor Therapeutics | 11.13M |
| Opus Genetics | 9.86M |
| Artiva Biotherapeutics | 251.00K |
AVIR News
- 5 weeks ago - Atea Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 6 weeks ago - Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Atea Pharmaceuticals price target raised to $7 from $6 at Morgan Stanley - TheFly
- 2 months ago - Atea Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 2 months ago - Atea Pharmaceuticals Earnings release: Q2 2026 - Filings
- 2 months ago - Atea Pharmaceuticals Slides: Q2 2026 - Filings
- 2 months ago - Atea Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 2 months ago - Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire